Comparison between outcomes of IgA nephropathy with nephrotic-range proteinuria and nephrotic syndrome: do podocytes play a role?

Ren Fail. 2022 Dec;44(1):1443-1453. doi: 10.1080/0886022X.2022.2113796.

Abstract

Background: Nephrotic syndrome (NS) and nephrotic-range proteinuria (NRP) are uncommon in IgA nephropathy (IgAN), and their clinicopathology and prognosis have not been discussed. Podocytes may play an important role in both clinical phenotypes.

Methods: We investigated 119 biopsy-proven IgAN patients with proteinuria over 2 g/d. The patients were divided into three groups according to proteinuria level: the overt proteinuria (OP) group, NS group, and NRP group. In addition, according to the severity of foot process effacement (FPE), the patients were divided into three groups: the segmental FPE (SFPE) group, moderate FPE (MFPE) group, and diffuse FPE (DFPE) group. The outcome was survival from a combined event defined by a doubling of the baseline serum creatinine and a 50% reduction in eGFR or ESRD.

Results: Compared with the NRP group, patients in the NS group had more severe microscopic hematuria, presented with more severe endocapillary hypercellularity and had a higher percentage of DFPE. The Kaplan-Meier curve showed that MFPE patients had a better outcome in the NRP group <50% of tubular atrophy/interstitial fibrosis. In the multivariate model, the NRP group (HR = 17.098, 95% CI = 3.835-76.224) was associated with an increased risk of the combined event, while MFPE (HR = 0.260, 95% CI = 0.078-0.864; p = 0.028) was associated with a reduced risk of the combined event. After the addition of renin-angiotensin system inhibitors (RASi), the incidence of the combined event in the MFPE group (HR = 0.179, 95% CI = 0.047-0.689; p = 0.012) was further reduced.

Conclusions: NS presented more active lesions and more severe FPE in IgAN. NRP was an independent risk factor for progression to the renal endpoint, while MFPE indicated a better prognosis in NRP without obvious chronic renal lesions, which may benefit from RASi.

Keywords: IgAN; nephrotic syndrome; nephrotic-range proteinuria; podocyte.

MeSH terms

  • Glomerulonephritis, IGA* / complications
  • Glomerulonephritis, IGA* / drug therapy
  • Glomerulonephritis, IGA* / pathology
  • Humans
  • Kidney / pathology
  • Nephrotic Syndrome* / complications
  • Nephrotic Syndrome* / etiology
  • Podocytes* / pathology
  • Proteinuria / pathology
  • Retrospective Studies

Grants and funding

This work was supported by the Research Project for Practice Development of National TCM Clinical Research Bases (Project No. JDZX2015202); the National Key R&D Program "Research on Modernization of Traditional Chinese Medicine" (Project No. 2019YFC1709903); the 2020 Guangdong Provincial Science and Technology Innovation Strategy Special Fund (Guangdong-Hong Kong-Macau Joint Lab, Project No. 2020B1212030006); and the State Key Laboratory of Dampness Syndrome of Chinese Medicine (Project No. SZ2021ZZ43).